Synbias Pharma/GeminiPharmChem

Pipelines

Advancing Cancer Treatments

Innovative APIs, Superior Results

At Synbias-Gemini Group, our research and development pipeline is dedicated to advancing cancer treatments through the development of innovative and highly effective active pharmaceutical ingredients (APIs). Our current R&D efforts are focused on expanding our portfolio with new and promising compounds. These efforts are backed by our state-of-the-art facilities and a team of highly skilled scientists committed to excellence.

Current R&D Projects:

Daunorubicin HCI (API): We are advancing the development of Daunorubicin HCI, an anthracycline antibiotic used in the treatment of various cancers. Our focus is on optimizing its production process to ensure high purity and stability.
Cladribine (API): Our research includes the development of Cladribine, a chemotherapeutic agent used to treat certain types of leukemia and multiple sclerosis. We are dedicated to ensuring that our Cladribine API meets the highest quality standards.
Cladribine – Premix: In addition to the API, we are developing a premixed formulation of Cladribine to provide a ready-to-use solution for clinical use. This formulation aims to improve the convenience and accuracy of dosing for healthcare providers.

We Use Essential Cookies Only

Our website uses only essential cookies that are necessary for its proper functioning. We do not use cookies for tracking or advertising purposes. For more details, please refer to our Privacy policy.